U.S. markets closed
  • S&P 500

    4,473.75
    -6.95 (-0.16%)
     
  • Dow 30

    34,751.32
    -63.07 (-0.18%)
     
  • Nasdaq

    15,181.92
    +20.39 (+0.13%)
     
  • Russell 2000

    2,232.91
    -1.54 (-0.07%)
     
  • Crude Oil

    72.60
    -0.01 (-0.01%)
     
  • Gold

    1,753.70
    -41.10 (-2.29%)
     
  • Silver

    22.92
    -0.89 (-3.72%)
     
  • EUR/USD

    1.1776
    -0.0050 (-0.42%)
     
  • 10-Yr Bond

    1.3310
    +0.0270 (+2.07%)
     
  • GBP/USD

    1.3795
    -0.0041 (-0.30%)
     
  • USD/JPY

    109.7100
    +0.3500 (+0.32%)
     
  • BTC-USD

    47,471.32
    -584.46 (-1.22%)
     
  • CMC Crypto 200

    1,217.93
    -15.36 (-1.25%)
     
  • FTSE 100

    7,027.48
    +10.99 (+0.16%)
     
  • Nikkei 225

    30,323.34
    -188.37 (-0.62%)
     

Inovio's Pan-COVID-19 Vaccine Candidate Can Provide Immune Responses Against Variants, Animal Study Shows

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Inovio Pharmaceuticals Inc (NASDAQ: INO) has announced results from a preclinical study of its next-generation Pan-COVID-19 vaccine candidate, INO-4802, that demonstrates its potential to induce cross-reactive immune responses against current and emerging viral variants.

  • Data showed the vaccine candidate induced potent neutralizing antibodies and T cell responses against the original Wuhan strain as well as against B.1.1.7 (U.K. variant), B.1.351 (South African variant), and P.1. (Brazilian variant) in preclinical models.

  • INO-4802 has potential as either a first-line vaccine or a boost for individuals previously immunized with various Wuhan-matched vaccines.

  • The company plans to conduct Phase 1/2 trials this year with INO-4802.

  • Earlier this week, the company announced positive data from the Phase 2 segment of its Phase 2/3 INNOVATE trial in the U.S., evaluating INO-4800, its DNA vaccine candidate for COVID-19.

  • INO-4800 will enter a global Phase 3 trial this summer.

  • Price Action: INO shares are trading 0.15% higher at $6.5 on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.